Ting Therapeutics Advances TT004 into Phase Ib Clinical Trials as a Potential Cisplatin Chemoprotective Therapy

Oct 23, 2026

San Diego, California Oct 22, 2026 (Issuewire.com) - Ting Therapeutics Advances TT004 into Phase Ib Clinical Trial as a Potential Chemoprotective Therapy for Cisplatin-Treated Patients

  • China IND Approved;
  • Phase Ib Trial Set to Begin Recruiting Patients at Eye and ENT Hospital of Fudan University in Shanghai

Ting Therapeutics, Inc., a biotechnology company developing therapies for treatment-related tissue injury, today announced that its lead candidate, TT004, has received IND approval in China and is advancing into Phase Ib clinical development as a potential chemoprotective therapy for patients receiving cisplatin chemotherapy.

Cisplatin is a highly effective cancer treatment, but its toxicities can substantially limit therapy. Approximately 40% of patients discontinue or modify chemotherapy because of treatment-related toxicities. Cisplatin can also cause permanent hearing loss in up to 80% of patients and acute kidney injury in approximately 30% of patients.

TT004 is designed to protect normal tissues from cisplatin toxicity while preserving its anticancer activity. In preclinical studies, TT004 increased survival following cisplatin exposure three-fold and reduced cisplatin-induced hearing loss and kidney injury by approximately 70%, without compromising cisplatin's anticancer effects.

"These findings support our vision of TT004 as a chemoprotective therapy that could improve the tolerability of cisplatin while maintaining its anticancer efficacy," said Jian Zuo, PhD, Co-Founder and CEO of Ting Therapeutics. "Our goal is to reduce the suffering caused by cisplatin treatment-related toxicities, help more patients receive and complete effective chemotherapy, and improve their long-term quality of life."

Ting Therapeutics recently licensed its China rights for TT004 to Rising Dragon, a Chinese biotechnology company, for development in China. The companies jointly developed TT004 as an oral tablet and obtained IND approval from China's Center for Drug Evaluation (CDE) for first-in-human clinical evaluation.

The Phase Ib trial, conducted in collaboration with oncologists and otolaryngologists at Eye and ENT Hospital of Fudan University in Shanghai, will evaluate the safety and tolerability of oral TT004 administered with standard-of-care cisplatin chemotherapy in patients with head and neck cancer. The study has received institutional ethics approval and is preparing to initiate patient recruitment.

TT004's protective effects have been demonstrated only in preclinical models and have not yet been shown in humans. This trial is the first clinical evaluation of TT004 and an important step toward determining whether these effects can be translated to cancer patients.

About Ting Therapeutics

Founded in 2018, Ting Therapeutics, Inc. develops novel and repurposed therapeutics to prevent and treat hearing loss and other treatment-related tissue injuries. The Company's pipeline targets hearing loss associated with chemotherapy, noise exposure, antibiotics, aging, and other causes.

Contact:
Jian Zuo, PhD, Co-Founder & CEO
Ting Therapeutics, Inc.
6868 Nancy Ridge Dr., San Diego, CA 92121
[email protected]

Ting Therapeutics

 

Source :Ting Therapeutics, Inc.

This article was originally published by IssueWire. Read the original article here.

More News

article.head.headline
Oct 22, 2026
The AI Agent Nobody Owns: Watch Expert Webinar On Your Newest Insider Threat

Right now, there is probably an AI agent running on a laptop somewhere in your network. It stores API keys and database passwords, can access your internal systems, and works without anyone watching. Nobody reviewed its access. Nobody owns it. If an employee had that much reach with that little oversight, you would call it an insider risk. So why do we still call the agent a productivity tool?

article.head.headline
Oct 22, 2026
Arista Warns of Critical VeloCloud SQL Injection Zero-Day Exploited in Attacks

Attackers are exploiting a zero-day SQL injection flaw in Arista's VeloCloud Orchestrator (VCO), the central management system for VeloCloud SD-WAN networks, the company said in an advisory on October 22. The flaw lets anyone who can log in to the orchestrator, even with a read-only customer account, gain operator privileges, the top level of control over it. For

article.head.headline
Oct 22, 2026
eMudhra to Exit Global SSL/TLS Business After 8 Intermediate CA Keys Found Easily Guessable

eMudhra, an Indian certificate authority (CA), will withdraw from its global SSL/TLS certificate business, its board decided on Thursday. The decision came five days after a researcher reported recovering the private keys of eight of its intermediate CA certificates. eMudhra said it will replace affected customers' certificates with free ones from partners, though its

article.head.headline
Oct 22, 2026
Samsung brings 14 refurbished Galaxy S24, S25 smartphones to Amazon in US, prices start at $489

Samsung has expanded its Certified Re-Newed programme to Amazon.com, offering 14 refurbished Galaxy S24 and S25 models starting at $489. The phones feature genuine Samsung parts, new batteries, 147 quality checks and a one-year limited manufacturer warranty.

article.head.headline
Oct 22, 2026
ThreatsDay: AI Secrets Leak, PingCAP Source Theft, Signal Hang-Up Flaw, Laravel Auth Bypass + 21 More

This week has already been rough for cybersecurity. Critical PHP and GitLab RCE flaws, serious Linux security bugs, compromised eMudhra certificates, a Node.js RCE flaw, a hacked LiteLLM release, and hundreds of hijacked Tor relays. That's a lot to deal with in just a few days. And the week isn't even over yet. But those big headlines are only half the story. Stolen passwords, exposed

article.head.headline
Oct 22, 2026
Trump Ties Disaster Aid to Votes as Midterm Fight Heats Up

President Trump and Vice President JD Vance have dangled FEMA money to disaster-struck states during recent campaign rallies.

article.head.headline
Oct 22, 2026
A.I. and Its Dangers Are Embedded In the Midterm Elections

The midterms are the first elections in which artificial intelligence is integrated into every major social media platform. Efforts to blunt its harms are uneven.

article.head.headline
Oct 22, 2026
Two CVSS 9.0 Linux KSMBD RCE Flaws Disclosed on Public Mailing Lists Before Kernel Fixes

Linux servers running KSMBD, the kernel's built-in SMB server, are exposed to two publicly reported remote code execution flaws rated 9.0 by Trend Micro's Zero Day Initiative, with no fix yet in the mainline kernel. One of them, ZDI-CAN-33774, can be triggered before any network authentication. The other, ZDI-CAN-33549, requires the SMB Direct transport and an RDMA-capable network

article.head.headline
Oct 22, 2026
Meta Ordered to Pay $25 Billion After Court Finds 43 Million Privacy Violations

Social media giant Meta was ordered to pay 25 billion in penalties by a New Mexico court on Wednesday as part of a data privacy lawsuit that sprang from the company's Cambridge Analytica data scandal, which came to light in 2018. According to multiple reports from the Associated Press, the New York Times, Reuters, and the Wall Street Journal, state District Court Judge Francis J. Mathew called

article.head.headline
Oct 22, 2026
PHP Security Flaw Sets Off Global Rush to Patch, Leaving Websites Offline

Governments and businesses around the world scrambled to prevent hackers from exploiting a vulnerability in PHP, a popular programming language.

article.head.headline
Oct 22, 2026
Storm Josephine sparks hurricane-force wind warning as towering 34-foot waves threaten waters off US East Coast

A hybrid storm is moving along the US East Coast, bringing dangerous conditions to Americans hundreds of miles from its center.

article.head.headline
Oct 22, 2026
Scientists pinpoint the exact sky that inspired Van Gogh's The Starry Night

Vincent Van Gogh's The Starry Night is one of the most iconic works of art ever produced - and now experts have discovered what the painting really shows.


YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Science Of The World

Science Of The World offers breaking in-depth news about the latest scientific discoveries and technologies in a user-friendly format.

NEWSLETTER